MedTrace Logo

Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis

NCT03961516 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 34

Last updated 2022-05-20

No results posted yet for this study

Summary

The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently sampled oral glucose tolerance test.

Conditions

  • Cystic Fibrosis
  • Cystic Fibrosis-related Diabetes
  • Cystic Fibrosis Liver Disease
  • Pancreatic Steatosis
  • Hepatic Steatosis

Interventions

DEVICE

Frequently Sampled Oral Glucose Tolerance Test and CGM

Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.

RADIATION

MRI Pancreas and Liver

Patients will undergo an MRI of the pancreas and liver

Sponsors & Collaborators

  • University Hospitals Cleveland Medical Center

    lead OTHER

Principal Investigators

  • Katherine Kutney, MD · University Hospitals Cleveland Medical Center

Eligibility

Min Age
6 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2021-08-30
Completion
2021-08-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03961516 on ClinicalTrials.gov